161 related articles for article (PubMed ID: 87199)
41. Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.
Killackey JJ; Killackey BA; Philp RB
Agents Actions; 1985 Dec; 17(2):192-6. PubMed ID: 2420162
[TBL] [Abstract][Full Text] [Related]
42. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of human lung cyclic nucleotide phosphodiesterases by proxyphylline, theophylline and their metabolites.
Selvig K; Bjerve KS
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):250-2. PubMed ID: 6291318
[TBL] [Abstract][Full Text] [Related]
44. PDE inhibitors: a new approach to treat metabolic syndrome?
Lugnier C
Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
[TBL] [Abstract][Full Text] [Related]
45. Studies on griseolic acid derivatives. I. Synthesis of substituted derivatives of griseolic acid at the N1, C6, C2' or C7' position and their biological activities.
Kaneko M; Murofushi Y; Kimura M; Yamazaki M; Iijima Y
Nucleic Acids Symp Ser; 1985; (16):89-92. PubMed ID: 3003711
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of 3',5'-cyclic nucleotide 3'-phosphohydrolase by a novel 1',2'-cyclic nucleotide.
Nair V; Wiechert RJ; Young DA
J Cyclic Nucleotide Res; 1982; 8(3):181-90. PubMed ID: 6187785
[No Abstract] [Full Text] [Related]
48. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
49. 1-(4-Aminophenyl)isoquinoline derivatives. Potent inhibitors of calcium-independent and calcium-dependent phosphodiesterases from rat cerebral cortex.
Davis CW; Walker KA
Biochem Pharmacol; 1984 Apr; 33(8):1205-12. PubMed ID: 6324818
[TBL] [Abstract][Full Text] [Related]
50. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
51. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
52. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
53. The metabolism of cyclic nucleotides in the guinea-pig pancreas. Cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase.
Methven P; Lemon M; Bhoola K
Biochem J; 1980 Feb; 186(2):491-8. PubMed ID: 6246887
[TBL] [Abstract][Full Text] [Related]
54. Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart.
Meyer W; Nose M; Schmitz W; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1984 Dec; 328(2):207-9. PubMed ID: 6098837
[TBL] [Abstract][Full Text] [Related]
55. Do conventional plasma cyclic nucleotide phosphodiesterase inhibitors really work in all situations?
Wood PJ; Pao G; Ross G; Smith C
Clin Chim Acta; 1981 Sep; 115(3):405-8. PubMed ID: 6271425
[No Abstract] [Full Text] [Related]
56. RMI 12330A, an inhibitor of cyclic nucleotide phosphodiesterases and adenylate cyclase in kidney preparations.
Hunt NH; Evans T
Biochim Biophys Acta; 1980 Jun; 613(2):499-506. PubMed ID: 6256001
[TBL] [Abstract][Full Text] [Related]
57. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
58. Effect of 3-isobutyl-1-methylxanthine and zaprinast on non-adrenergic non-cholinergic relaxation in the rat gastric fundus.
Barbier AJ; Lefebvre RA
Eur J Pharmacol; 1992 Jan; 210(3):315-23. PubMed ID: 1377130
[TBL] [Abstract][Full Text] [Related]
59. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
Davey DD; Erhardt PW; Cantor EH; Greenberg SS; Ingebretsen WR; Wiggins J
J Med Chem; 1991 Sep; 34(9):2671-7. PubMed ID: 1654425
[TBL] [Abstract][Full Text] [Related]
60. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
